Cargando…

Antipsychotics-induced improvement of cool executive function in individuals living with schizophrenia

Cool executive dysfunction is a crucial feature in people living with schizophrenia which is related to cognition impairment and the severity of the clinical symptoms. Based on electroencephalogram (EEG), our current study explored the change of brain network under the cool executive tasks in indivi...

Descripción completa

Detalles Bibliográficos
Autores principales:	Si, Yajing, Liu, Congcong, Kou, Yanna, Dong, Zhao, Zhang, Jiajia, Wang, Juan, Lu, Chengbiao, Luo, Yanyan, Ni, Tianjun, Du, Yunhong, Zhang, Hongxing
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2023
Materias:	Psychiatry
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10172485/ https://www.ncbi.nlm.nih.gov/pubmed/37181875 http://dx.doi.org/10.3389/fpsyt.2023.1154011

Ejemplares similares

Estimation of the cool executive function using frontal electroencephalogram signals in first-episode schizophrenia patients
por: Yu, Yi, et al.
Publicado: (2016)

Executive Functioning in Schizophrenia
por: Orellana, Gricel, et al.
Publicado: (2013)

Antipsychotics, Metabolic Adverse Effects, and Cognitive Function in Schizophrenia
por: MacKenzie, Nicole E., et al.
Publicado: (2018)

Hypofunctional Dopamine Uptake and Antipsychotic Treatment-Resistant Schizophrenia
por: Amato, Davide, et al.
Publicado: (2019)

Influence of antipsychotics on metabolic syndrome risk in patients with schizophrenia
por: Koricanac, Aleksandra, et al.
Publicado: (2022)

Readmission Rates of Patients with Schizophrenia Treated with Depot Antipsychotics versus Oral Antipsychotics in a Community Hospital
por: Espiridion, Eduardo D, et al.
Publicado: (2018)

Brain Networks Reveal the Effects of Antipsychotic Drugs on Schizophrenia Patients and Controls
por: Towlson, Emma K., et al.
Publicado: (2019)

Analysis of polyunsaturated fatty acids in antipsychotic-free individuals with at-risk mental state and patients with first-episode schizophrenia
por: Le, Anh Thi Phuong, et al.
Publicado: (2023)

Serum Epidermal Growth Factor is Low in Schizophrenia and Not Affected by Antipsychotics Alone or Combined With Electroconvulsive Therapy
por: Zhang, Xiaobin, et al.
Publicado: (2020)

Association of Serotonin(2c) Receptor Polymorphisms With Antipsychotic Drug Response in Schizophrenia
por: Li, Jiang, et al.
Publicado: (2019)

Schizophrenia treatment with a combination of two LAI antipsychotics: A case report
por: Jarosz, Marcin, et al.
Publicado: (2022)

Adverse effects of antipsychotics on sleep in patients with schizophrenia. Systematic review and meta-analysis
por: Valencia Carlo, Yarmila Elena, et al.
Publicado: (2023)

Executive Dysfunction among Children with Antipsychotic Treated Schizophrenia
por: Wiguna, Tjhin, et al.
Publicado: (2014)

Which Subgroup of First-Episode Schizophrenia Patients Can Remit During the First Year of Antipsychotic Treatment?
por: Cheng, Zhang, et al.
Publicado: (2020)

Cognitive Behavioral Therapy for Insomnia as Adjunctive Therapy to Antipsychotics in Schizophrenia: A Case Report
por: Izuhara, Muneto, et al.
Publicado: (2018)

Treatment Responses of Cognitive Function and Plasma Asymmetric Dimethylarginine to Atypical Antipsychotic in Patients With Schizophrenia
por: Yu, Zhi-min, et al.
Publicado: (2019)

Targeting mGlu Receptors for Optimization of Antipsychotic Activity and Disease-Modifying Effect in Schizophrenia
por: Nicoletti, Ferdinando, et al.
Publicado: (2019)

Predictors for Antipsychotic Dosage Change in the First Year of Treatment in Schizophrenia Spectrum and Bipolar Disorders
por: Ringen, Petter Andreas, et al.
Publicado: (2019)

The More, the Merrier…? Antipsychotic Polypharmacy Treatment Strategies in Schizophrenia From a Pharmacology Perspective
por: Hjorth, Stephan
Publicado: (2021)

Prescription of Anticholinergic Drugs in Patients With Schizophrenia: Analysis of Antipsychotic Prescription Patterns and Hospital Characteristics
por: Hori, Hikaru, et al.
Publicado: (2022)

Effects of adjunctive pimavanserin and current antipsychotic treatment on QT interval prolongation in patients with schizophrenia
por: Bugarski-Kirola, Dragana, et al.
Publicado: (2022)

Non-antipsychotic medicines and modified electroconvulsive therapy are risk factors for hospital-acquired pneumonia in schizophrenia patients
por: Yang, Yan, et al.
Publicado: (2023)

Failure of Conflict to Modulate Central Executive Network Activity Associated with Delusions in Schizophrenia
por: Speechley, William J., et al.
Publicado: (2013)

The Effects of Antipsychotic Treatment on the Brain of Patients With First-Episode Schizophrenia: A Selective Review of Longitudinal MRI Studies
por: Yang, Chengmin, et al.
Publicado: (2021)

Gyrification Connectomes in Unmedicated Patients With Schizophrenia and Following a Short Course of Antipsychotic Drug Treatment
por: Nelson, Eric A., et al.
Publicado: (2018)

Changes in Brain Structure, Function, and Network Properties in Patients With First-Episode Schizophrenia Treated With Antipsychotics
por: Yin, Ping, et al.
Publicado: (2021)

Third-generation antipsychotics in patients with schizophrenia and non-responsivity or intolerance to clozapine regimen: What is the evidence?
por: Vasiliu, Octavian
Publicado: (2022)

Impairment of Executive Functions Associated With Lower D-Serine Serum Levels in Patients With Schizophrenia
por: Hons, Jaromir, et al.
Publicado: (2021)

Relationship between Brain-Derived Neurotrophic Factor and Schneiderian First Rank Symptoms in Antipsychotic-Naïve Schizophrenia
por: Kalmady, Sunil Vasu, et al.
Publicado: (2013)

Pharmacological Interventions to Treat Antipsychotic-Induced Dyslipidemia in Schizophrenia Patients: A Systematic Review and Meta Analysis
por: Kanagasundaram, Pruntha, et al.
Publicado: (2021)

Uric Acid Potential Role in Systemic Inflammation and Negative Symptoms After Acute Antipsychotic Treatment in Schizophrenia
por: Borovcanin, Milica M., et al.
Publicado: (2022)

Effects of Antipsychotic Administration on Brain Glutamate in Schizophrenia: A Systematic Review of Longitudinal (1)H-MRS Studies
por: Egerton, Alice, et al.
Publicado: (2017)

Reduced Cell-Free Mitochondrial DNA Levels Were Induced by Antipsychotics Treatment in First-Episode Patients With Schizophrenia
por: Ouyang, Houxian, et al.
Publicado: (2021)

Long-Acting Injectable Antipsychotic Treatment in Schizophrenia and Co-occurring Substance Use Disorders: A Systematic Review
por: Coles, Alexandria S., et al.
Publicado: (2021)

Medication Gaps and Antipsychotic Polypharmacy in Previously Hospitalized Schizophrenia Patients: An Electronic Cohort Study in Three Canadian Provinces
por: Peters, Evyn, et al.
Publicado: (2022)

Genetic and Metabolite Variability in One-Carbon Metabolism Applied to an Insulin Resistance Model in Patients With Schizophrenia Receiving Atypical Antipsychotics
por: Ward, Kristen M., et al.
Publicado: (2021)

Antipsychotic Drug Utilization and Adverse Drug Reaction Profiling in Patients With Schizophrenia at a Tertiary Care Hospital in Western India
por: Tripathi, Raakhi K, et al.
Publicado: (2022)

Adherence to oral second-generation antipsychotic medications in patients with schizophrenia and bipolar disorder: physicians’ perceptions of adherence vs. pharmacy claims
por: Stephenson, J J, et al.
Publicado: (2012)

Anterior Cingulate Cortex Glutamate Levels Are Related to Response to Initial Antipsychotic Treatment in Drug-Naive First-Episode Schizophrenia Patients
por: Li, Jinguang, et al.
Publicado: (2020)

Changes in Body Fat and Related Biochemical Parameters Associated With Atypical Antipsychotic Drug Treatment in Schizophrenia Patients With or Without Metabolic Syndrome
por: Kornetova, Elena G., et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_5kjadh42702bf8cl1jrs9hlssj